|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
DK1399484T3
(da)
*
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
AU2003244817B2
(en)
*
|
2002-06-28 |
2010-08-26 |
Domantis Limited |
Antigen-binding immunoglobulin single variable domains and dual-specific constructs
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
EP1578801A2
(en)
*
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
KR101151957B1
(ko)
†
|
2004-07-22 |
2012-06-01 |
로저 킹돈 크레이그 |
결합 분자
|
|
EP1699826B1
(en)
|
2005-01-05 |
2009-03-11 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
RU2423381C2
(ru)
|
2005-07-25 |
2011-07-10 |
Трабьон Фармасьютикалз, Инк. |
Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
|
|
JP2009519011A
(ja)
*
|
2005-12-01 |
2009-05-14 |
ドマンティス リミテッド |
インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
|
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
|
US20070264687A1
(en)
*
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
|
JP5167155B2
(ja)
*
|
2006-03-09 |
2013-03-21 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
|
|
NZ573646A
(en)
*
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
JP2010528647A
(ja)
*
|
2007-06-06 |
2010-08-26 |
ドマンティス リミテッド |
ポリペプチド、抗体可変ドメインおよびアンタゴニスト
|
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
|
KR20100058509A
(ko)
*
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
|
KR101658247B1
(ko)
|
2008-01-03 |
2016-09-22 |
더 스크립스 리서치 인스티튜트 |
모듈 인식 도메인을 통한 항체 표적화
|
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
|
BRPI0909044B8
(pt)
|
2008-03-14 |
2021-05-25 |
Transgene Sa |
anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
AU2009324354B2
(en)
*
|
2008-12-10 |
2016-04-14 |
Ablynx Nv |
Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
|
|
ES2724975T3
(es)
|
2009-12-10 |
2019-09-18 |
Regeneron Pharma |
Ratones que producen anticuerpos de cadena pesada
|
|
KR101688522B1
(ko)
*
|
2009-12-15 |
2016-12-21 |
삼성전자주식회사 |
안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
|
|
CA2785907A1
(en)
*
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
SMT202600080T1
(it)
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
EP2420253A1
(en)
*
|
2010-08-20 |
2012-02-22 |
Leadartis, S.L. |
Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
|
|
EP3604339B1
(en)
|
2011-01-14 |
2021-03-10 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
HUE047278T2
(hu)
|
2011-08-05 |
2020-04-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
HK1204926A1
(en)
*
|
2012-02-29 |
2015-12-11 |
吉联亚生物科技有限公司 |
Antibodies to matrix metalloproteinase 9
|
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたＦｃ領域を含む抗原結合分子
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
US10150800B2
(en)
|
2013-03-15 |
2018-12-11 |
Zyngenia, Inc. |
EGFR-binding modular recognition domains
|
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
|
RU2671089C2
(ru)
*
|
2013-09-16 |
2018-10-29 |
Хельмхольтц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) |
Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
|
|
KR102813659B1
(ko)
*
|
2013-11-11 |
2025-05-28 |
추가이 세이야쿠 가부시키가이샤 |
개변된 항체 가변영역을 포함하는 항원 결합 분자
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
EA035419B9
(ru)
|
2014-05-29 |
2020-08-07 |
Мэкроудженикс, Инк. |
Триспецифичные связывающие молекулы и способы их применения
|
|
WO2015197582A1
(en)
*
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Monomeric multispecific antigen binding proteins
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
TWI831044B
(zh)
|
2014-11-11 |
2024-02-01 |
日商中外製藥股份有限公司 |
抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
|
|
RU2017129236A
(ru)
|
2015-01-26 |
2019-03-07 |
Макродженикс, Инк. |
Мультивалентные молекулы, содержащие dr5-связывающие домены
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
BR112018006817A2
(pt)
|
2015-10-08 |
2018-10-23 |
Macrogenics Inc |
método de tratamento do câncer
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
|
GEP20227398B
(en)
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
TWI767915B
(zh)
|
2016-06-27 |
2022-06-21 |
加州大學董事會 |
Ror-1與btk拮抗劑的組合
|
|
CA3048211A1
(en)
|
2016-12-23 |
2018-06-28 |
Macrogenics, Inc. |
Adam9-binding molecules, and methods of use thereof
|
|
AU2018224094B2
(en)
|
2017-02-24 |
2025-04-17 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
TW201938194A
(zh)
|
2017-12-05 |
2019-10-01 |
日商中外製藥股份有限公司 |
包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
|
|
KR20200098590A
(ko)
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
|
JP7337079B2
(ja)
|
2018-02-15 |
2023-09-01 |
マクロジェニクス，インコーポレーテッド |
変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
|
MX2021000827A
(es)
|
2018-08-03 |
2021-03-25 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
|
|
US12509524B2
(en)
|
2018-09-28 |
2025-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule comprising altered antibody variable region
|
|
CN115243763A
(zh)
|
2020-01-08 |
2022-10-25 |
里珍纳龙药品有限公司 |
治疗进行性骨化性纤维发育不良
|
|
IL295434A
(en)
|
2020-02-21 |
2022-10-01 |
Macrogenics Inc |
cd137 binding molecules and their uses
|
|
CR20220541A
(es)
|
2020-03-31 |
2022-11-28 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
|
|
EP4175650A1
(en)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|